二丙酸倍氯米松联合酮替芬防治毛细支气管炎后婴幼儿哮喘的研究

目的　观察低剂量二丙酸倍氯米松和酮替芬联合应用能否降低毛细支气管炎后支气管哮喘患病率。方法　 5 6例毛细支气管炎患儿为治疗组 ,采用低剂量二丙酸倍氯米松局部吸入 ,口服酮替芬 ,疗程 6～ 9个月 ;32例毛细支气管炎患儿不用药作为对照组。临床随访≥ 1年 ,观察两组患儿哮喘发生率。同时检测治疗前、后患儿肺功能及骨密度。结果　完成随访 1年以上者 ,治疗组 5 2例中仅 3例 (5 77% )发生哮喘 ,而对照组 30例中有 14例 (4 6 6 7% )发生哮喘 ,两组比较有显著性差异 (P <0 0 1)。治疗组患儿肺功能与治疗前比较亦有显著性差异。两组骨密度检测治疗前、后比较无显著差异。结论　低剂量二丙酸倍氯米松局部吸入与酮替芬联合应用可降低毛细支气管炎后婴幼儿哮喘患病率     

Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan.

Stenotrophomonas maltophilia has become an important nosocomial pathogen in immunocompromised patients in Taiwan. Patients with underlying diseases such as diabetes, uremia, and solid malignancy are extremely vulnerable to this organism. S. maltophilia bacteremia has a mortality rate of up to 62% if appropriate antibiotics are not instituted early. Knowledge of the risk factors for infection as well as local susceptibility patterns is helpful in determining which patients should receive empirical antibiotics active against S. maltophilia. This study assessed the characteristics of 50 episodes of S. maltophilia bacteremia in 48 patients admitted between March 3, 1999 and May 21, 2003. The new fluoroquinolone levofloxacin showed promising in vitro activity against S. maltophilia in view of the increasing resistance of isolates to trimethoprim-sulfamethoxazole. For patients at risk for S. maltophilia infection, such as those receiving mechanical ventilation in the ICU or those with multiple vascular access devices, the need for antimicrobial agents to which S. maltophilia is normally sensitive should be considered in selecting empiric therapy.     

胃肠内镜

内镜光学相干CT检测Barrett食管不典型增生的准确性：一项前瞻性、双盲研究；在无线食管pH监测期间有功能性胃灼热患更可能出现胸骨后不适；Barrett食管的冷冻消融术：一项先导性研究。     

冷冻干燥法制备阿糖胞苷冻干脂质体粉针研究

本文采用冷冻干燥法制备阿糖胞苷冻干脂质体粉针，并建立了质量控制标准。在扫描电镜和透射电镜观察下，将此脂质体冻干品加注射用水溶解后，能很快重新形成脂质体。算术平均粒径为０．４７５６±０．０８３３μｍ，包封率约３０％。     

K562／ADM耐药细胞株的建立及其生物学特性的初步观察

我们建立的K562/ADM耐药细胞株,在ADM浓度为2.4μg/m1(4.46μM)中已稳定培养3.5个月,传了30—35代,K562/ADM亦具有多药耐受件(Multidrug Resistance,MDR)的特点,对ADM、VCR、AT—1258和DDP的耐受性分别为K562的114.7、94.0、13.3和7.4倍,但对5—FU不产生交叉耐药。K562和K562/ADM的倍增时间分别为19.2h和52.8h,集落生成率分别为37.5％和11.1％,K562染色体数为34—68,中位数为56;K562/MDM染色体数为32—90,中位数为50,K562/ADM可做为耐药机理和克服耐药措施研究的极好模型。     

刺激兔扣带回对尾核头部痛相关单位电活动的影响

实验在15只家兔上进行。以玻璃微电极记录尾核头部(DHCN)痛相关单位,刺激扣带回,观察痛相关单位电活动的变化。在70只DHCN痛相关单位中,有44个对刺激扣带回表现兴奋反应(62.9％),17个呈抑制反应(24.3％),9个变化不明显(12.8％)。进一步观察了52只痛相关单位,在刺激扣带回后再施伤害刺激,43个原痛兴奋单位中15个转为抑制(34.9％),16个进一步兴奋(37.2％)12个无变化(27.9％);原9个痛抑制单位,8个转为兴奋,1个变化不明显。提示,扣带回可通过其下行活动,调制伤害性冲动在尾核水平上的传递。     

新疆奎屯地区口腔粘膜疾病调查

本文介绍新疆奎屯地区常见口腔粘膜疾病患病情况,其罹患率与上海地区同类调查相比,除白斑外其他病种罹患率均偏高,可能与生活水平偏低或某些全身疾病有关。     

北京地区361名孕妇乙型肝炎流行病学研究

从1985年4月到1986年4月对361名孕妇进行的乙型肝炎流行病学横断面研究以及196名产妇一年随访研究的结果表明,361例孕妇的HBsAg阳性率为2.5%,抗-HBs阳性率为23.8%,抗-HBc阳性率为22.1%,HBV总感染率为31.3%;抗-HBs阳性、抗-HBs和抗-HBc共存阳性者占总阳性者的76.1%,说明人群感染HBV后大多产生了免疫力.1986年4月复查了196例产妇,133名在1985年HBV标记阴性者中有6人获得了HBV标记,HBV新感染率为4.5%;1例为急性乙型肝炎病人,5例为亚临床感染.HBV新感染者的感染途径不明,但医源性传播不能排除.1986年检查的148对夫妇中,男性HBsAg阳性率是女性的3.1倍(6.1%对2.0%),男性单独抗-HBc阳性率是女性的2.3倍(6.1%对2.7%),抗-HBs、抗-HBs和抗-HBc共存以及HBV感染率男女性间都无显著差异.     

艾氟隆无痛止血海绵用于鼻中隔手术后填塞止血效果观察

鼻腔黏膜神经末梢十分丰富，鼻腔手术后一直采用凡士林纱条作为填塞止血材料，但在填入和撤出过程中常给病人带来难以忍受的痛苦。因此，我院采用艾氟隆无痛止血海绵这一新型的填寒止血材料，安全且耐受性好，减轻了病人的痛苦，提高了治疗效果，得到了病人和医生的一致认可。     

Amorphous oxide--a platform for drug delivery.

Usually, a drug is loaded onto the metallic surface of a medical device by applying a polymer layer containing the drug. Unfortunately, polymer coatings on the metallic surface may exhibit numerous problems after implantation, such as late thrombosis, inflammation, and restenosis. Current research was conducted to investigate whether a suitable oxide layer can be used as a polymer-free platform for drug loading, especially for cardiovascular stents. The loading of heparin onto, as well as eluting of heparin from, the amorphous oxide film on the 316LVM stainless steel wire was confirmed by experimental studies using cyclic voltammetry (CV), electrochemical impedance spectroscopy (EIS), electron spectroscopy for chemical analysis (ESCA), high-performance liquid chromatography (HPLC), and activated clotting time (ACT). Evidence shows that amorphous oxide can be an ideal substitute for the polymer coating of drug-loaded stents to minimize metallic corrosion, inflammation, late-thrombosis, and restenosis.